SLP 0905 - Sealife Pharma
Alternative Names: SLP-0905Latest Information Update: 15 Jan 2024
At a glance
- Originator Sealife Pharma
- Class Antibacterials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial endocarditis; Nosocomial infections
Most Recent Events
- 06 Sep 2023 Preclinical trials in Bacterial endocarditis in Austria (Parenteral) (Sealife Pharma pipeline, September 2023)
- 06 Sep 2023 Preclinical trials in Nosocomial infections in Austria (Parenteral) (Sealife Pharma pipeline, September 2023)
- 06 Sep 2023 Pharmacokinetics and pharmacodynamics data from preclinical trial in Gram positive bacterial infections (Sealife Pharma pipeline, September 2023)